Breast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Yun-Ji | - |
dc.contributor.author | Kang, Jong Soon | - |
dc.contributor.author | Lee, Su In | - |
dc.contributor.author | Son, Dong Min | - |
dc.contributor.author | Yun, Jieun | - |
dc.contributor.author | Baek, Ji Young | - |
dc.contributor.author | Kim, Sang Kyum | - |
dc.contributor.author | Lee, Kiho | - |
dc.contributor.author | Park, Song-Kyu | - |
dc.date.accessioned | 2021-09-03T20:34:58Z | - |
dc.date.available | 2021-09-03T20:34:58Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 1792-1074 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87678 | - |
dc.description.abstract | Triple negative breast cancer (TNBC), which does not express the progesterone, estrogen, or HER2/neu receptor, is aggressive and difficult to treat. Paclitaxel, a tubulin stabilizing agent, is one of the most frequently prescribed anticancer agents for breast cancers, including TNBC. Residual disease that occurs due to resistance or partial resistance of cancer cells in a tumor against anticancer agents is the most important issue in oncology. In the present study, when MDA-MB-231 cells, a TNBC cell line, were treated with 30 mu M paclitaxel, a slightly higher concentration than its GI(50) value, for 6 days, a small number of cells with different morphologies survived. Among the surviving cells, small round cells were isolated, cloned, and named MDA-MB-231-JYJ cells. MDA-MB-231-JYJ cells were observed to be highly proliferative and tumorigenic. In addition, signal transduction molecules involved in proliferation, survival, malignancy, or stemness of cancer cells, such as c-Src, c-Met, Notch 1, c-Myc, Sox2, Oct3/4, Nanog, and E-cadherin were highly expressed or activated. While further study is required, MDA-MB-231-JYJ cells appear to have some of the characteristics of cancer precursor cells. Although MDA-MB-231-JYJ cells were isolated from the cells that survived in the continuous presence of paclitaxel, they were not resistant to paclitaxel but developed resistance to dasatinib, a Bcr-Abl and Src kinase family inhibitor. The activated state of Src and Notch 1, and the expression levels of c-Myc and cyclins in MDA-MB-231-JYJ cells were less affected than MDA-MB-231 cells by the treatment of dasatinib, which may explain the resistance of MDA-MB-231-JYJ cells to dasatinib. These results suggest that cancer cells that become resistant to dasatinib during the process of paclitaxel therapy in patients may appear, and caution is required in the design of clinical trials using these two agents. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.subject | HETEROGENEITY | - |
dc.subject | MECHANISMS | - |
dc.subject | INHIBITOR | - |
dc.subject | DOCETAXEL | - |
dc.subject | APOPTOSIS | - |
dc.subject | LEUKEMIA | - |
dc.subject | KINASES | - |
dc.subject | TAXOL | - |
dc.title | Breast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Song-Kyu | - |
dc.identifier.doi | 10.3892/ol.2016.4852 | - |
dc.identifier.scopusid | 2-s2.0-84979650360 | - |
dc.identifier.wosid | 000382211900089 | - |
dc.identifier.bibliographicCitation | ONCOLOGY LETTERS, v.12, no.3, pp.2153 - 2158 | - |
dc.relation.isPartOf | ONCOLOGY LETTERS | - |
dc.citation.title | ONCOLOGY LETTERS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 2153 | - |
dc.citation.endPage | 2158 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | HETEROGENEITY | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | LEUKEMIA | - |
dc.subject.keywordPlus | KINASES | - |
dc.subject.keywordPlus | TAXOL | - |
dc.subject.keywordAuthor | breast cancer | - |
dc.subject.keywordAuthor | dasatinib | - |
dc.subject.keywordAuthor | paclitaxel | - |
dc.subject.keywordAuthor | drug resistance | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.